BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7918126)

  • 1. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
    van Hoesel QG; Verweij J; Catimel G; Clavel M; Kerbrat P; van Oosterom AT; Kerger J; Tursz T; van Glabbeke M; van Pottelsberghe C
    Ann Oncol; 1994 Jul; 5(6):539-42. PubMed ID: 7918126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of docetaxel in advanced soft tissue sarcomas.
    Edmonson JH; Ebbert LP; Nascimento AG; Jung SH; McGaw H; Gerstner JB
    Am J Clin Oncol; 1996 Dec; 19(6):574-6. PubMed ID: 8931674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase II study of docetaxel in patients with advanced stage soft tissue sarcoma].
    Amodio A; Carpano S; Paoletti G; Gionfra T; Rinaldi M; Manfredi C; Foggi P; Lopez M
    Clin Ter; 1998; 149(2):121-5. PubMed ID: 9780476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
    ten Bokkel Huinink WW; Prove AM; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
    Ann Oncol; 1994 Jul; 5(6):527-32. PubMed ID: 7918124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
    Verweij J; Lee SM; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola ED; van Glabbeke M; Tonelli D; Judson IR
    J Clin Oncol; 2000 May; 18(10):2081-6. PubMed ID: 10811673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.
    Verweij J
    Anticancer Drugs; 1995 Jul; 6 Suppl 4():19-24. PubMed ID: 8745350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
    Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
    Muthalib A; Darwis I; Prayogo N; Sutjipto
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():498-504. PubMed ID: 10895201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
    Verweij J; Catimel G; Sulkes A; Sternberg C; Wolff I; Aamdal S; van Hoesel Q
    Eur J Cancer; 1995; 31A Suppl 4():S21-4. PubMed ID: 7577101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
    Robinet G; Thomas P; Pérol M; Vergnenègre A; Lena H; Taytard A; Paillotin D; Bessa EH; Schuller-Lebeau MP
    Rev Mal Respir; 2000 Feb; 17(1):83-9. PubMed ID: 10756559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
    Köstler WJ; Brodowicz T; Attems Y; Hejna M; Tomek S; Amann G; Fiebiger WC; Wiltschke CH; Krainer M; Zielinski CC
    Ann Oncol; 2001 Sep; 12(9):1281-8. PubMed ID: 11697841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
    Perng RP; Shih JF; Chen YM; Chou KC; Lee YC; Tsai CM
    Jpn J Clin Oncol; 2000 Oct; 30(10):429-34. PubMed ID: 11185888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
    Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
    Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of Taxotere (docetaxel) as a new treatment in breast cancer.
    Fumoleau P; Chevallier B; Kerbrat P; Dieras V; Azli N; Bayssas M; Van Glabbeke M
    Breast Cancer Res Treat; 1995; 33(1):39-46. PubMed ID: 7749131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
    Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
    Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study.
    Balcerzak SP; Benedetti J; Weiss GR; Natale RB
    Cancer; 1995 Dec; 76(11):2248-52. PubMed ID: 8635028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.